Our Research and Development Pipeline
Our research and development activities are focused on:
- Cardiovascular diseases
- Diabetic and metabolic disorders
- Bone/joint diseases
- Infectious diseases
- Cancer
- Immunological/allergic diseases
In 2009, the research and development budget was totally €1.5 billion, representing 20.7% of net sales, which is significantly higher than the industry average. A summary of the major compounds that are currently under development is shown in the table.
| Development code number |
Class or application |
Developmental stage |
| Cardiovascular | ||
|
CS - 8635 |
Hypertension |
Phase III |
|
Edoxaban |
Oral anticoagulant (factor Xa inhibitor) |
Phase III |
| Diabetes | ||
|
Rivoglitazone |
Diabetes (PPAR gamma agonist) |
Phase III |
| Cancer | ||
|
CS - 7017 |
Oncology (PPAR gamma agonist) |
Phase II |
| ARQ 197 |
Oncology | Phase II |
| U3 1287 |
Oncology (HER-3 antibody) |
Phase I |
| Immune Disorders / Autoimmunity | ||
|
CS - 0777 |
Immunomodulator (S1P1 modulator) |
Phase I |
